SuperworthCNS Pharmaceuticals CNSP
- Market cap
- $7.3M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $3.4M+55% | $4.3M+43% | $2.4M−32% | $1.1M−61% | $4.2M+25% | $1.5M−65% | $3.2M+33% | $1.2M+5% | $2.2M−48% | $3.2M+111% | $3.5M+9% | $1.2M+3% |
| SG&A | $1.1M−7% | $1.1M−49% | $1.1M−18% | $1.4M+20% | $1.4M+23% | $1.7M+54% | $1.1M−2% | $1.2M−12% | $1.1M−24% | $2.8M+66% | $1.4M+31% | $1.5M+21% |
| −$4.5M+33% | −$5.4M+5% | −$3.5M−28% | −$2.5M−37% | −$5.6M+24% | −$3.2M−41% | −$4.3M+22% | −$2.4M−5% | −$3.3M−42% | −$6M+87% | −$5M+15% | −$2.7M+12% | |
| Interest expense | $1.8K+242% | $2.9K+25% | $6.6K+22% | $4.5K+22% | $2.3K+23% | $2.8K−4% | $6.2K−6% | $4.2K−6% | $2.1K−6% | $2.7K−2% | $6.1K−2% | $4K−4% |
| Net income | −$4.5M+32% | −$5.4M+5% | −$3.5M−28% | −$2.5M−37% | −$5.6M+24% | −$3.2M−41% | −$4.3M+21% | −$2.4M−6% | −$3.2M−43% | −$6M+88% | −$4.9M+15% | −$2.6M+9% |
| −$32484.00−58% | −$31800.00−70% | −$12245.76−84% | −$4049.20−87% | −$153.20−100% | n/a | −$18.93−100% | −$6.42−100% | −$5.76−96% | n/a | −$7.30−61% | −$0.38−94% | |
| 139+213% | 169+242% | 290+356% | 625+384% | 36.6K+26181% | n/a | 227.2K+78387% | 370.1K+59120% | 558.9K+1427% | n/a | 676.2K+198% | 6.8M+1748% |
EPS, diluted: 6 periods, Q4 FY18 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY18 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest CNS Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CNSPCNS Pharmaceuticals | $7.3M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $52.3M | 11.8× | 12.1× | 1.4× | +6% | 8.4% |
More on CNS Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .